AU2020278162A1 - Processes and intermediates for preparing a BTK inhibitor - Google Patents

Processes and intermediates for preparing a BTK inhibitor Download PDF

Info

Publication number
AU2020278162A1
AU2020278162A1 AU2020278162A AU2020278162A AU2020278162A1 AU 2020278162 A1 AU2020278162 A1 AU 2020278162A1 AU 2020278162 A AU2020278162 A AU 2020278162A AU 2020278162 A AU2020278162 A AU 2020278162A AU 2020278162 A1 AU2020278162 A1 AU 2020278162A1
Authority
AU
Australia
Prior art keywords
compound
formula
reaction
group
ibrutinib
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2020278162A
Other languages
English (en)
Inventor
Cheng Yi Chen
Andras Horvath
Philip James Pye
Jinxiong SU
Simon Albert WAGSCHAL
Shuo Wang
Yuanyuan YUAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of AU2020278162A1 publication Critical patent/AU2020278162A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
AU2020278162A 2019-05-21 2020-05-20 Processes and intermediates for preparing a BTK inhibitor Abandoned AU2020278162A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/087823 2019-05-21
CN2019087823 2019-05-21
PCT/EP2020/064123 WO2020234381A1 (en) 2019-05-21 2020-05-20 Processes and intermediates for preparing a btk inhibitor

Publications (1)

Publication Number Publication Date
AU2020278162A1 true AU2020278162A1 (en) 2021-11-18

Family

ID=70857160

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020278162A Abandoned AU2020278162A1 (en) 2019-05-21 2020-05-20 Processes and intermediates for preparing a BTK inhibitor

Country Status (11)

Country Link
US (1) US12215110B2 (cg-RX-API-DMAC10.html)
EP (1) EP3972977A1 (cg-RX-API-DMAC10.html)
JP (1) JP7658916B2 (cg-RX-API-DMAC10.html)
KR (1) KR20220011668A (cg-RX-API-DMAC10.html)
CN (1) CN113874378A (cg-RX-API-DMAC10.html)
AU (1) AU2020278162A1 (cg-RX-API-DMAC10.html)
BR (1) BR112021022347A2 (cg-RX-API-DMAC10.html)
CA (1) CA3135240A1 (cg-RX-API-DMAC10.html)
IL (1) IL288154A (cg-RX-API-DMAC10.html)
MX (1) MX2021014246A (cg-RX-API-DMAC10.html)
WO (1) WO2020234381A1 (cg-RX-API-DMAC10.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12450495B2 (en) 2022-06-13 2025-10-21 International Business Machines Corporation Neural capacitance: neural network selection via edge dynamics

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2529621B1 (en) * 2006-09-22 2016-10-05 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase
UY32531A (es) 2009-03-31 2010-10-29 Boehringer Ingelheim Int Nuevos compuestos para el tratamiento de trastornos del snc
CN103121999A (zh) * 2012-08-29 2013-05-29 苏州迪飞医药科技有限公司 一种酪氨酸激酶抑制剂pci-32765的合成方法
EP2970291B1 (en) * 2013-03-15 2022-05-11 Janssen Pharmaceutica, N.V. Processes and intermediates for preparing a medicament
US9156847B2 (en) 2013-03-15 2015-10-13 Janssen Pharmaceutica Nv Processes and intermediates for preparing a medicament
MX365614B (es) 2013-10-17 2019-06-07 Blueprint Medicines Corp Composiciones utiles para tratar trastornos relacionados con kit.
MA41350A (fr) 2015-01-14 2017-11-21 Janssen Pharmaceutica Nv Synthèse d'un inhibiteur de la tyrosine kinase de bruton
RU2712440C2 (ru) 2015-02-12 2020-01-29 Шанхай Дьюд Медикал Сайенс Энд Текнолоджи Ко., Лтд Способ получения ибрутиниба

Also Published As

Publication number Publication date
CN113874378A (zh) 2021-12-31
MX2021014246A (es) 2022-01-06
BR112021022347A8 (pt) 2021-12-28
US12215110B2 (en) 2025-02-04
KR20220011668A (ko) 2022-01-28
US20220204516A1 (en) 2022-06-30
CA3135240A1 (en) 2020-11-26
IL288154A (en) 2022-01-01
WO2020234381A1 (en) 2020-11-26
JP7658916B2 (ja) 2025-04-08
BR112021022347A2 (pt) 2022-01-04
JP2022533747A (ja) 2022-07-25
EP3972977A1 (en) 2022-03-30

Similar Documents

Publication Publication Date Title
CN108699063B (zh) 一种芦可替尼的合成工艺
EP2970291B1 (en) Processes and intermediates for preparing a medicament
JP7153705B2 (ja) Ｂｔｋ阻害剤を調製するプロセス
US9156847B2 (en) Processes and intermediates for preparing a medicament
CN107176955B (zh) 一种巴瑞替尼的制备方法
CN113336761B (zh) 一种jak抑制剂关键中间体的制备方法
CN109485638B (zh) 一种奥希替尼中间体的制备方法
AU2022269229B2 (en) Process for preparing btk inhibitors
CN105392772B (zh) 奥格列汀的关键中间体的制备方法
US12215110B2 (en) Processes and intermediates for preparing a Btk inhibitor
RU2818458C2 (ru) Способы и промежуточные соединения для получения ингибитора btk
HK40060540A (en) Processes and intermediates for preparing a btk inhibitor
CN103373948A (zh) 一种天然产物(-)-海人草酸的制备方法
JP7774448B2 (ja) Ｂｔｋ阻害剤を調製するためのプロセス及び中間体
JP2022517411A (ja) テトラヒドロピリドピリミジン類の調製方法
JP2026513909A (ja) （１ｒ，２ｓ，５ｒ）－１－アミノ－５－［２－（ジヒドロキシボラニル）エチル］－２－［（ジメチルアミノ）メチル］シクロヘキサン－１－カルボン酸を生産するための方法

Legal Events

Date Code Title Description
MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application